Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Applied Genetic Technologies Corp (AGTC): Steve Cohen Starts New Stake With 5.8% of The Company’s Outstanding Stock

Steve Cohen’s Point72 Asset Management disclosed today a new position in Applied Genetic Technologies Corp (NASDAQ:AGTC). The funds affiliated with Mr. Cohen (Point72 Asset Management, Point72 Capital Advisors and EverPoint Asset Management) own, in aggregate, more than 957,834 shares of Common Stock, of which Mr. Cohen can be deemed –indirect- beneficial ownership. This stake represents 5.8% of the company’s outstanding stock.

Point72 Asset Management is a Connecticut-based group of hedge funds founded and managed by Steven A. Cohen. As the successor to Mr. Cohen’s legendary SAC Capital Advisors, the firm manages his personal assets, and those of certain eligible employees, and focuses primarily on discretionary long/short equity investing. Despite being headquartered in Stamford, Connecticut, it maintains offices in New York, Boston, Hong Kong, Tokyo and Singapore.


Applied Genetic Technologies Corp (NASDAQ:AGTC) is a $304 million market cap clinical-stage biotechnology company working on the development of gene therapy products designed to transform the lives of patients with severe inherited orphan diseases in ophthalmology. It went public in late-March, and closed its initial public offering of 2 million shares of its common stock at a price to the public of $15.00 per share, before underwriting discounts, on July 30.

When investing in Applied Genetic Technologies Corp (NASDAQ:AGTC) Mr. Cohen is probably betting on growth: analysts expect the stock to rise about 70% over the next year, while Stifel initiated coverage last week, with a “buy” rating.

In addition to Point 72, other major institutional investors are also bullish about Applied Genetic Technologies Corp (NASDAQ:AGTC). This is the case of Jacob Gottlieb’s Visium Asset Management, which disclosed ownership of 392,625 shares by the end of the second quarter of 2014. Another prominent fund that acquired the company’s stock after the IPO is Israel Englander’s Millennium Management, which last declared holding 32,468 of Common Stock.

As outlined in a previous article, trailing Mr. Cohen’s picks can prove to be quite profitable. His previous hedge fund, SAC Capital Advisors, returned around 30% over the last 20 years. Moreover, his success in the healthcare sector has been plenty. Back in November of 2013, Mr. disclosed a large increase in its stake in Intercept Pharmaceuticals Inc (NASDAQ:ICPT), to 5.3% of the company’s total outstanding stock. A couple of months later, Intercept Pharmaceutical’s stock inched about 600% in just one day, registering the highest intraday growth in the NASDAQ history. Needless to say, Mr. Cohen’s picking eye is pretty sharp.

Disclosure: Javier Hasse holds no positions in any stocks or funds mentioned

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!